(function(){ var content_array=["

关于<\/b>Novaliq
<\/b>Novaliq是一家生物制药公司，专注于基于全球首款无水技术EyeSol®的一流和同类最佳眼科疗法的开发和商业化。<\/p> \n

EyeSol®是Novaliq专有的无水技术，采用在物理、化学和生理学上均呈惰性的超纯半氟代烷烃（SFA），具有出色的生物相容性和非常好的安全性。Novaliq提供行业领先的产品组合，以满足数百万眼疾患者当今尚未得到满足的医疗需求。<\/p> \n

2022年7月宣布了向美国食品药品监督管理局（FDA）提交的新药申请（NDA），寻求NOV03（全氟己基辛烷）的批准，用于治疗与睑板腺功能障碍（MGD）相关的干眼病（DED）的体征和症状。除了CyclASol®外，公司还根据其经过验证的EyeSol®平台，在眼科和皮肤科等相邻适应症方面继续推进更多的管道机会。<\/p> \n

Novaliq GmbH总部位于德国海德堡，Novaliq Inc.在美国马萨诸塞州剑桥设有办事处。长期股东是生命和健康科学公司投资机构 Hopp BioTech holding GmbH & Co. KG。更多详情请访问www.novaliq.com<\/a>。 <\/p> \n

推荐<\/b>阅读<\/b><\/p> \n

    \n
  1. Leonardi A, Modugno RL, & Salami E. Allergy and Dry Eye Disease. Ocular immunology and inflammation. 2021; 29:1168–1176<\/li> \n
  2. 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope<\/li> \n
  3. Starr CE, Gupta PK, Farid M, Beckman KA, Chan CC, Yeu E, Gomes JAP, Ayers BD, Berdahl JP, Holland EJ, Kim T, Mah FS (the ASCRS Cornea Clinical Committee). An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019; 45:669–684<\/li> \n
  4. Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022; 48:623–629<\/li> \n
  5. White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, Karpecki PM. Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye. Clin Ophthalmol. 2019; 13:2285-2292<\/li> \n
  6. Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care. 2021; 27:S23-32<\/li> \n
  7. Sheppard JD, Wirta DL, McLaurin E, Boehmer BE, Ciolino CB, Meides AS, Schlüter T, Ousler GW, Usner D,  Krösser S. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase II\/III ESSENCE Study. Cornea. 2021; 40:1290-1297<\/li> \n
  8. Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jentsch G, Beckert M, Ousler GM, Steven P, Krösser S. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology. 2019; 126:793-800<\/li> \n<\/ol> \n

    任何<\/i>产品<\/i>\/<\/i>品牌名称和<\/i>\/<\/i>或<\/i>标志均为各自所有者的商标。<\/i> © 2022 Novaliq GmbH, Heidelberg<\/span>, Germany<\/span>.<\/i><\/p> \n

    Novaliq<\/b>媒体<\/b>联系人：<\/b>
    Simone Angstmann-Mehr<\/span>
    info@novaliq.com<\/a>
    +49 6221 50259-0<\/p>"]; $("#dvExtra").html(content_array[0]);})();